Why Shares of Akebia Therapeutics Were Up Tuesday
Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight kidney disease, has seen its shares climb more than 168% so far this year.
On Monday, the company announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing approval for Vafseo (vadadustat) to treat anemia connected with chronic kidney disease in adults on maintenance dialysis. The drug was already approved in April by the European Commission and in Japan in 2020.
That wasn't the only bit of good news for Akebia: The stock's rise has meant that it is no longer in danger of being delisted on the Nasdaq.
Source Fool.com
Akebia Therapeutics Inc. Aktie
Leichtes Buy-Übergewicht bei der Akebia Therapeutics Inc. Aktie mit 8 zu 3 Einschätzungen.
Bei einem Kursziel von 3 € ergibt sich ein Potenzial von 134.19%, was mehr als eine Verdopplung des aktuellen Kurses von 1.28 € für Akebia Therapeutics Inc. bedeuten würde.
